In addition, setmelanotide is pioneering a personalized medicine approach to obesity, specifically targeting very rare genetic disorders such as pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, and leptin receptor deficiency. The gene discussed is POMC; the disease is obesity due to melanocortin 4 receptor deficiency.